Snake Venom Components as Therapeutic Leads: A Critical Narrative Review of Established Medicines and Translational Barriers
Uzuazokaro Mark-Maria Agatemor *
Research and Development Department, First Focus Research, Nottingham, United Kingdom.
*Author to whom correspondence should be addressed.
Abstract
Background: Snake venoms contain biologically active molecules that interact with enzymes, adhesion receptors and ion channels. These interactions have informed drug development, although toxicity and poor translation constrain many proposed applications.
Objective: To critically examine the therapeutic relevance of snake venom components, distinguish demonstrated clinical utility from experimental activity, and identify requirements for further development.
Approach: Targeted web searches of PubMed-indexed records and original publisher pages were conducted on 13 September 2026. Foundational discovery studies, randomised trials and selected mechanistic investigations were prioritised. Public prescribing information was consulted for established medicines. Evidence was organised by mechanism and experimental setting without meta-analysis or formal certainty grading.
Findings: Bradykinin-potentiating peptides and disintegrins informed the development of captopril, eptifibatide and tirofiban. Their translation depended on molecular redesign and clinical evaluation rather than administration of crude venom. Defibrinogenating and fibrinolytic candidates illustrate less successful pathways: ancrod produced inconsistent stroke outcomes, and alfimeprase did not improve the principal clinical endpoint in placebo-controlled peripheral arterial occlusion studies. Textilinin-1, anticancer disintegrins, antimicrobial enzymes and mambalgins provide mechanistic leads. However, normal-cell toxicity, problematic cancer models and differences between rodent and human ion-channel pharmacology limit extrapolation.
Conclusion: Snake venom is a productive source of pharmacological templates. Future progress requires defined molecular products, human-relevant target validation, exposure-linked safety assessment and clinically meaningful comparators. Claims of therapeutic benefit should reflect the level of evidence for each individual molecule.
Keywords: Snake venom, drug discovery, disintegrins, haemostasis, phospholipase A2, L-amino acid oxidase, mambalgins, translational pharmacology